Spectral AI Business Summary

Spectral AI, Inc. (MDAI) is a predictive medical diagnostics company that specializes in the development of AI-driven imaging systems for wound care, primarily focusing on burns and chronic wounds. The company is currently transitioning from a research-heavy business model, historically sustained by high-value government R&D contracts with the Biomedical Advanced Research and Development Authority (BARDA), to a commercial-scale enterprise. Revenue is increasingly generated through a licensing and recurring service model for its flagship DeepView System, a non-invasive, algorithm-driven diagnostic tool that provides clinicians with immediate assessments of a wound's healing potential. In the competitive landscape of advanced wound care and medical imaging, Spectral AI competes directly with firms such as MolecuLight, Sanara MedTech (SMTI), Kent Imaging, and WoundVision. The company distinguishes itself as a high-tech innovator by replacing subjective clinical assessments with objective, deep-learning-based diagnostics, positioning it as a specialized leader in the $12 billion global wound care market. Leadership at Spectral AI is anchored by a team with deep expertise in medicine, law, and finance. Effective February 9, 2026, Vincent S. Capone assumed the role of Chief Executive Officer, having previously served as the company’s CFO and General Counsel; his background includes senior roles at KPMG, Reed Smith LLP, and leadership within private equity. The company was co-founded by Executive Chairman Dr. J. Michael DiMaio, a prominent cardiothoracic surgeon, and Wensheng Fan, who previously served as CEO and remains a key strategic figure. The board of directors includes notable industry veterans such as Lead Independent Director Richard Cotton and Erich Spangenberg. Spectral AI is backed by significant institutional and private investors, including Glazer Capital, Hudson Bay Capital, and Highlander Partners, reflecting strong capital market interest in its transition toward full-scale commercialization following its 2025 FDA submission milestones.